SISRAM MED (01696) has disclosed that its board received notification on April 8, 2026, from the company's controlling shareholder, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. To optimize the internal equity structure, two indirect wholly-owned subsidiaries of Fosun Pharma—Neng Yue Limited and Chindex Medical Limited—entered into share transfer agreements on the same date with another indirect wholly-owned subsidiary of Fosun Pharma, Fosun Pharma Industrial Pte. Ltd. (FPI). Under these agreements, Neng Yue agreed to transfer all of its 207,186,160 shares in the company (representing approximately 44.24% of the total issued shares as of the announcement date), and Chindex Medical agreed to transfer all of its 127,318,640 shares (representing approximately 27.18% of the total issued shares) to FPI. The proposed restructuring is subject to the fulfillment of certain conditions before it can be completed. Upon completion of the proposed restructuring, FPI will obtain 71.42% of the voting rights in the company, triggering an obligation under the Code on Takeovers and Mergers and Share Repurchases for a mandatory general offer. Consequently, Fosun Pharma has applied for, and the Securities and Futures Commission has granted, an exemption from the obligation to make a general offer for the company’s shares arising from this proposed restructuring.